Meg E. Fasulo

Current Representations

ViiV Healthcare v. Gilead Sciences, Inc. (D. Del.)
Counsel for Gilead in patent infringement case related to Gilead's Biktarvy HIV treatment. Case pending.

Adverio Pharma GmbH et al. v. Alembic Pharmaceuticals, Ltd. et al. (D. Del.)
Trial counsel for plaintiffs in Hatch-Waxman litigation relating to Bayer's Adempas® (riociguat) product. Case pending.

Gilead Sciences, Inc. v. Regents of the University of Minnesota, IPR2017-01712, IPR2017-01753, IPR2017-2004, and IPR2017-2005 (U.S. Patent & Trademark Office)
Counsel for Gilead in inter partes review proceedings before the Patent Trial and Appeal Board. Gilead filed four petitions for review of U.S. Patent No. 8,815,830, owned by the University of Minnesota, arguing in pertinent part that the patent is invalid as both obvious and anticipated by specific prior art references. Petitions pending.

Regents of the University of Minnesota v. Gilead Sciences, Inc. (N.D. Cal.)
Trial counsel for Gilead in patent infringement action related to Gilead's hepatitis C treatments. Case pending.

Other Representative Cases

Regents of the Univ. of Minn. v. LSI Corp., et al. (Fed. Cir.)
Counsel for permissive intervenor Gilead Sciences in case of first impression regarding application of state sovereign immunity to inter partes review proceedings before the United States Patent and Trademark Office. In a precedential opinion on June 14, 2019, the Federal Circuit held that States were not immune from such proceedings. The Supreme Court later denied the University's petition for writ of certiorari in what was identified by Law360 as one of the "Biggest Patent Rulings Of 2019." Read about the case here

UroPep v. Eli Lilly (Fed. Cir.)
Appellate counsel for UroPep, securing a plaintiff verdict in a patent infringement jury trial concerning Eli Lilly's sales of Cialis to treat benign prostatic hyperplasia (BPH).